Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,014Revenue $M37.0Net Margin (%)-140.4Altman Z-Score-2.0
Enterprise Value $M841EPS $-0.3Operating Margin %-244.0Piotroski F-Score1
P/E(ttm)--Beneish M-Score10.6Pre-tax Margin (%)-140.4Higher ROA y-yN
Price/Book7.710-y EBITDA Growth Rate %-29.4Quick Ratio3.5Cash flow > EarningsN
Price/Sales22.25-y EBITDA Growth Rate %-45.7Current Ratio3.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-18.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-61.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M242ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ARNA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARNAKen Fisher 2013-12-31 Buy $4.08 - $6.66
($5.22)
$ 4.20-20%New holding11,000
ARNAMario Gabelli 2011-03-31 Sold Out $1.41 - $2.16
($1.7)
$ 4.20147%Sold Out0
ARNAMario Gabelli 2010-12-31 Buy $1.27 - $2.38
($1.58)
$ 4.20166%New holding13,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARNA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARNA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
WOODS RANDALL EDirector 2015-03-30Sell76,268$4.49-6.46view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-03-17Sell70,000$5-16view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-01-08Sell45,000$6.26-32.91view
SHANAHAN WILLIAM R JRSVP & Chief Medical Officer 2015-01-07Sell50,000$5.49-23.5view
LIEF JACKChairman, President and CEO 2014-07-01Sell223,525$5.85-28.21view
BELCHER DONALD DDirector 2014-06-27Sell2,473$5.85-28.21view
SPECTOR STEVEN WEVP, General Counsel & Sec 2014-05-12Sell45,000$7.05-40.43view
BELCHER DONALD DDirector 2014-05-06Sell4,176$7-40view
HIXSON HARRY F JRDirector 2014-04-22Sell36,900$6.31-33.44view
Nova Tina SusanDirector 2014-04-14Sell35,000$6.22-32.48view

Press Releases about ARNA :

    Quarterly/Annual Reports about ARNA:

    News about ARNA:

    Articles On GuruFocus.com
    Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
    (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 
    WEEKLY CFO SELLS HIGHLIGHT: ZNGA, ARNA, JACK, TUMI, PANW Apr 07 2013 
    comment on ARNA Mar 15 2013 
    comment on ARNA Mar 02 2013 
    WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC Oct 07 2012 
    Arena Facing Increased Pressure from Peers Apr 23 2012 
    Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
    Vivus Could Rocket on Success of Qnexa Apr 13 2012 
    These 4 Biotech Stocks Are a Buy Now Feb 08 2012 

    More From Other Websites
    ARENA PHARMACEUTICALS INC Financials May 19 2015
    Arena Sport 24 months free of charge May 15 2015
    Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at Upcoming Medical... May 14 2015
    Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at Upcoming Medical... May 14 2015
    5 Key Takeaways Following Arena's Q1 Results May 13 2015
    10-Q for Arena Pharmaceuticals, Inc. May 13 2015
    5 New Biotech Developments Worth Watching May 13 2015
    Arena Pharmaceuticals 1Q Loss Narrower-Than-Expected - Analyst Blog May 12 2015
    Arena Pharmaceuticals reports 1Q loss May 11 2015
    Arena Pharmaceuticals reports 1Q loss May 11 2015
    Arena Pharmaceuticals Inc Earnings call Call scheduled for 5:00 pm ET today May 11 2015
    ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 11 2015
    Arena Pharmaceuticals and Roivant Sciences Enter into Collaboration for Nelotanserin, a Novel... May 11 2015
    Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2015 Financial Results May 11 2015
    Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2015 Financial Results May 11 2015
    Arena Pharmaceuticals and Roivant Sciences Enter into Collaboration for Nelotanserin, a Novel... May 11 2015
    Q1 2015 Arena Pharmaceuticals Inc Earnings Release - After Market Close May 11 2015
    Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference May 08 2015
    Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference May 08 2015
    Will Arena Pharmaceuticals (ARNA) Surprise this Earnings? - Analyst Blog May 07 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK